Piper Jaffray analyst Michael Lavery revisited the four Canadian licensed producers under his coverage, namely Aurora Cannabis (ACB), Canopy Growth (CGC), Cronos Group (CRON) and Tilray (TLRY). The analyst continues to believe Canopy and Cronos look best positioned. Both companies have strong cash positions to facilitate growth and have good visibility on key strategic priorities, Lavery tells investors in a research note. The analyst cut his estimates for Tilray, but he keeps an Overweight rating on the shares as he still sees growth potential in both Europe and the U.S. Lavery believes Aurora lacks visibility on key strategic growth priorities and he keeps a Neutral rating on the shares. The analyst lowered his price target for Aurora to $4 from $7, for Canopy to $36 from $40, for Cronos to $12 from $18, and for Tilray to $31 from $72.
previous post